UBS initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $12 price target As one of the more potent anti-fibrotics UBS has seen after the recent Phase 2b data, Sagimet’s fatty acid synthase inhibitor denifanstat could have a place particularly in move severe F3 patients, the analyst tells investors in a research note. The firm says competitive data and unique mechanism of action with a safe oral could carve out share for denifanstat in a large metabolic dysfunction-associated steatohepatitis market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGMT:
- Sagimet Biosciences, Inc. Class A (SGMT) Q3 Earnings Cheat Sheet
- Sagimet Biosciences completes End-of-Phase 2 meeting with FDA on denifanstat
- Sagimet Biosciences to present Phase 2b data of denifanstat at AASLD 2024
- Sagimet Biosciences announces Phase 2b FASCINATE trial met primary endpoint
- 3 Penny Stocks to Watch Now, 10/3/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
